Design Therapeutics (DSGN) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $15.00 price target on the stock.
Design Therapeutics Maps H2 Data Readouts for RESTORE-FA, FECD Biomarker Study and DM1 Program [Yahoo! Finance]
Design Therapeutics (DSGN) had its price target raised by Royal Bank Of Canada from $13.00 to $14.00. They now have an "outperform" rating on the stock.
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates [Yahoo! Finance]
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates